Nona Christina N, Nobrega José N
Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Behavioural Neurobiology Laboratory, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Behavioural Neurobiology Laboratory, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; Departments of Psychiatry and Psychology, University of Toronto, Toronto, ON, Canada.
Behav Brain Res. 2018 Jan 15;336:269-281. doi: 10.1016/j.bbr.2017.09.024. Epub 2017 Sep 14.
Mechanisms underlying differential sensitivity to behavioural sensitization to ethanol (EtOH) remain poorly understood, although accumulating evidence suggests a role for glutamatergic processes in the ventral striatum. Efforts to address this issue can benefit from the well-documented fact that in any given cohort, some of the mice (High sensitized; HS) show robust sensitization, while others (Low sensitized; LS) show little, if any, sensitization. Here, we examined whether this variability might be differentially associated with nucleus accumbens (NAc) glutamate processes. Male DBA mice received 5 EtOH (2.2g/kg) or saline injections twice a week and were challenged with EtOH (1.8g/kg) 2 weeks after injection 5. When an EtOH challenge was administered 2 weeks following the induction of sensitization, HS, but not LS, mice showed a robust increase in glutamate levels (67%, P<0.01) as measured by in vivo microdialysis. In a separate cohort, the mGlu2/3 agonist LY354740 (10mg/kg), given prior to the EtOH challenge, abolished the expression of sensitization. To ascertain whether enhanced release could also be observed during the induction of sensitization, glutamate levels were measured after the 1st and 5th EtOH injection and were found to be unchanged in HS mice, although briefly elevated in LS mice at injection 5. To further assess possible glutamate involvement during the induction of sensitization, sensitizing EtOH injections were co-administered with NMDAR antagonists. At the doses used, MK-801 (0.25mg/kg) and CGS 19755 (10mg/kg) blocked the expression of sensitization, but did not significantly interfere with the development of EtOH sensitization. Within the limitations of the present design, the results suggest an important role for EtOH-induced glutamate release in the NAc when sensitization is well established, but not necessarily during the development of sensitization.
尽管越来越多的证据表明腹侧纹状体中的谷氨酸能过程发挥了作用,但对乙醇(EtOH)行为敏化的差异敏感性背后的机制仍知之甚少。在任何给定的群体中,有充分的证据表明,一些小鼠(高敏化;HS)表现出强烈的敏化,而另一些小鼠(低敏化;LS)则几乎没有敏化(如果有的话)。解决这个问题的努力可以从这一有据可查的事实中受益。在这里,我们研究了这种变异性是否可能与伏隔核(NAc)的谷氨酸过程存在差异关联。雄性DBA小鼠每周接受5次EtOH(2.2g/kg)或生理盐水注射,并在第5次注射后2周用EtOH(1.8g/kg)进行激发。当在敏化诱导后2周给予EtOH激发时,通过体内微透析测量,HS小鼠而非LS小鼠的谷氨酸水平显著升高(67%,P<0.01)。在另一个群体中,在EtOH激发前给予mGlu2/3激动剂LY354740(10mg/kg),消除了敏化的表达。为了确定在敏化诱导过程中是否也能观察到释放增强,在第1次和第5次EtOH注射后测量了谷氨酸水平,发现HS小鼠的谷氨酸水平没有变化,尽管LS小鼠在第5次注射时短暂升高。为了进一步评估在敏化诱导过程中谷氨酸可能的参与情况,将敏化性EtOH注射与NMDAR拮抗剂共同给药。在所使用的剂量下,MK-801(0.25mg/kg)和CGS 19755(10mg/kg)阻断了敏化的表达,但并未显著干扰EtOH敏化的发展。在本设计的局限性范围内,结果表明,当敏化充分建立时,EtOH诱导的谷氨酸在NAc中释放起重要作用,但在敏化发展过程中不一定如此。